This author has yet to write their bio.Meanwhile lets just say that we are proud old admin contributed a whooping 84 entries.
May 14, 2019 Impact Level: Moderate The LIBERTY 1 study met its primary efficacy endpoint with 73.4% of women receiving once daily oral relugolix combination therapy achieving the responder criteria compared with 18.9% of women receiving placebo (p < 0.0001). Response was defined as a menstrual blood loss volume of less than 80 mL and […]
May 7, 2019 Impact level: Moderate Sutro has provided updates on preclinical BCMA ADC and BCMA/CD3 bispecific antibody programs that are part of a Celgene immuno-oncology collaboration formed in 2014.
April 25, 2019 Impact level: High According to an updated label, FDA has granted accelerated approval to use of Keytruda (pembrolizumab; PD-1) in combination with Inlyta (axitinib; TKI) in 1L renal cell carcinoma (RCC).
April 22, 2019 Impact Level: High Novartis has contributed $75 million towards a Series C financing for CAR-T company Poseida, which totaled $142 million from current and new investors.
